Free tool
FAERS Monitor: Enspryng
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761149 or its brand name (Enspryng, Satralizumab). Reports on generic versions are filed under their own applications.
Reports
1,789
Serious
1,398
78% of reports
Hospitalization
705
Death reported
102
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neuromyelitis optica spectrum disorder305
- off label use176
- urinary tract infection140
- pneumonia114
- covid-1975
- no adverse event75
- fatigue66
- hypoaesthesia56
- infection56
- headache54
- pain49
- arthralgia46
- muscular weakness44
- optic neuritis39
- sepsis37
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2020 | 12 |
| 2021 | 130 |
| 2022 | 210 |
| 2023 | 343 |
| 2024 | 373 |
| 2025 | 403 |
| 2026 | 317 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,370 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neuromyelitis optica spectrum disorderSignal | 305 | 3437.9 | 3052.6 | 808,403 |
| optic neuritisSignal | 39 | 50.7 | 37.1 | 1,843 |
| urinary tract infectionSignal | 140 | 9.7 | 8.2 | 1,086 |
| covid-19Signal | 75 | 5.0 | 4.0 | 240 |
| no adverse eventSignal | 75 | 4.9 | 3.9 | 229 |
| muscular weaknessSignal | 44 | 4.6 | 3.4 | 119 |
| infectionSignal | 56 | 4.6 | 3.5 | 153 |
| hypoaesthesiaSignal | 56 | 4.4 | 3.4 | 145 |
| pneumoniaSignal | 114 | 4.1 | 3.5 | 273 |
| sepsisSignal | 37 | 3.9 | 2.8 | 77 |
| off label useSignal | 176 | 2.4 | 2.1 | 143 |
| arthralgia | 46 | 1.3 | 1.0 | 3 |
| headache | 54 | 1.0 | 0.8 | 0 |
| fatigue | 66 | 1.0 | 0.8 | 0 |
| pain | 49 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.